Currently, the disease is usually found too late to save lives
Reporting on a small preliminary study, Johns Hopkins researchers say a simple blood test based on detection of tiny epigenetic alterations may reveal the earliest signs of pancreatic cancer, a disease that is nearly always fatal because it isn’t usually discovered until it has spread to other parts of the body.
The findings of their research, if confirmed, they say, could be an important step in reducing mortality from the cancer, which has an overall five-year survival rate of less than 5 percent and has seen few improvements in survival over the last three decades.
“We have mammograms to screen for breast cancer and colonoscopies for colon cancer but we have had nothing to help us screen for pancreatic cancer,” says Nita Ahuja, M.D., an associate professor of surgery, oncology and urology at the Johns Hopkins University School of Medicine and leader of the study described online this month in the journal Clinical Cancer Research. “While far from perfect, we think we have found an early detection marker for pancreatic cancer that may allow us to locate and attack the disease at a much earlier stage than we usually do.”
For their study, Ahuja and her colleagues were able to identify two genes, BNC1 and ADAMTS1, which together were detectable in 81 percent of blood samples from 42 people with early-stage pancreatic cancer, but not in patients without the disease or in patients with a history of pancreatitis, a risk factor for pancreatic cancer. By contrast, the commonly used PSA antigen test for prostate cancer only picks up about 20 percent of prostate cancers.
Ahuja and her colleagues found that in pancreatic cancer cells, it appears that chemical alterations to BNC1 and ADAMTS1 — epigenetic modifications that alter the way the genes function without changing the underlying DNA sequence — silence the genes and prevent them from making their protein product, the role of which is not well-understood. These alterations are caused by the addition of a methyl group to the DNA.
Using a very sensitive method called Methylation on Beads (MOB) developed by Jeff Tza-Huei Wang, Ph.D., a professor at the Whiting School of Engineering at Johns Hopkins, the researchers were able to single out, in the blood, even the smallest strands of DNA of those two genes with their added methyl groups. The technique uses nanoparticle magnets to latch on to the few molecules being shed by the tumors, which are enough to signal the presence of pancreatic cancer in the body, the researchers found.
Specifically, researchers say, they found BNC1 and ADAMTS1 in 97 percent of tissues from early-stage invasive pancreatic cancers. Surgery is the best chance for survival in pancreatic cancer, because radiation and chemotherapy are not very effective against it. The smaller the cancer — the earlier it is detected — the more likely surgery will be successful and the patient will survive.
Ahuja says the practical value of any blood test for cancer markers depends critically on its sensitivity, meaning the proportion of tumors it detects, and its specificity, meaning how many of the positive results are false alarms. The specificity of this new pair of markers is 85 percent, meaning 15 percent would be false alarms. Ahuja says she hopes further research will help refine the test, possibly by adding another gene or two, in order to go over 90 percent in both sensitivity and specificity.
Ahuja also cautions that her team still needs to duplicate the results in a larger sample of tumors, but is encouraged by the results so far. She says she doesn’t envision the blood test as a means of screening the general population, the way mammograms and colonoscopies are used to find early breast and colon cancers. Instead, she imagines it would be best used in people at high risk for developing the disease, such as those with a family history of pancreatic cancer, a previous case of pancreatitis, long-term smokers or people with the BRCA gene mutations, which are linked to breast, ovarian and pancreatic cancers.
“You have to optimize your medical resources,” says Ahuja, who hopes a commercial blood test might one day only cost $50.
Go deeper with Bing News on:
- Essex: My friend had pancreatic cancer. Here's how the Chiefs healed us.on February 4, 2020 at 8:30 am
At one level, sports are silly. We fans scream and pout and swear and crow over teenagers and multimillionaires, seemingly convinced that their athletic feats make a real difference in our lives. But ...
- PharmaCyte Biotech Will Have All the Protection It Needs for Pancreatic Cancer Treatment Upon Marketing Approvalon February 4, 2020 at 6:00 am
NEW YORK, NY, Feb. 04, 2020 (GLOBE NEWSWIRE) -- PharmaCyte Biotech (OTCQB: PMCB) is about to embark upon a planned U.S. FDA Phase 2b clinical trial to treat locally advanced, inoperable pancreatic ...
- Watch Out For These Pancreatic Cancer Signs When Going To The Toileton February 4, 2020 at 5:24 am
Symptoms associated with pancreatic cancer oftentimes do not appear during the early stage of the disease. This makes the life-threatening ailment very hard for doctors to diagnose. To avoid late ...
- BACH1 gene regulator facilitates pancreatic cancer metastasison February 3, 2020 at 11:04 pm
A multidisciplinary team of researchers at Japan's Tohoku University has found that a gene regulator, called BACH1, facilitates the spread of pancreatic cancer to other parts of the body. The ...
- Jackie Caplinger raises pancreatic cancer awareness while caring for husbandon February 3, 2020 at 9:50 am
He called his doctor and after ten days of tests, a very different diagnosis came back. He had stage one pancreatic cancer. Caplinger’s wife, Jackie, quickly became his team manager, cheerleader and ...
Go deeper with Google Headlines on:
Go deeper with Bing News on:
Pancreatic cancer blood test
- High levels of carbon dioxide in body could make pancreatic cancer worse: Studyon January 30, 2020 at 5:03 am
Those afflicted face difficulty in breathing, which in turn results in a decrease in the levels of oxygen in the blood, and raises the levels of CO2 dissolved in the blood. This condition, marked by ...
- What You Should Know About Pancreatic Canceron January 30, 2020 at 2:44 am
Pancreatic cancer has a five-year survival rate in just the single digits and has no early detection tests and no effective long-term treatments. Unless the cancer is surgically removed in its ...
- High carbon dioxide levels due to respiratory diseases may aggravate pancreatic canceron January 29, 2020 at 9:35 am
Often a result of many years of smoking, the disease makes it hard to breathe, leaving patients with lower levels of oxygen and higher levels of carbon dioxide in their blood. Low oxygen, called ...
- Bluestar Genomics' breakthrough study highlights promising data for multi-cancer detection from a single blood drawon January 29, 2020 at 5:02 am
Breast, lung, pancreatic, and prostate cancer make up 41% of the cancer incidence in ... "Our research data outperforms screening PSA testing, the current standard of care screening blood test for ...
- PharmaCyte Biotech's Pancreatic Cancer Therapy Passes Critical FDA-Required Tests as Countdown to IND Submission Beginson January 27, 2020 at 5:00 am
NEW YORK, NY, Jan. 27, 2020 (GLOBE NEWSWIRE) -- PharmaCyte Biotech (OTCQB:PMCB) announced that its clinical trial product, which will be employed during the company's upcoming Phase 2b clinical trial ...